MKMileen R. D. van de Kar

Mileen R. D. van de Kar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mileen R. D. van de Kar has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improved patient value after implementing same day discharge for patients undergoing pulmonary vein isolation

    by Stacey R Slingerland, Mileen R D van de Kar, Jasper Vermeer, Gijs J van Steenbergen, Daniela N Schulz, Dennis van Veghel, Lukas Dekker

    Aims: Pulmonary vein isolation (PVI) is an effective intervention to treat atrial fibrillation, which is increasingly prevalent. Same-day discharge (SDD) is a strategic approach to limit procedure-related costs. This study aimed to compare healthcare utilization, costs, and clinical outcomes before and after implementation of an SDD protocol. Methods and results: This retrospective study included 2987 patients undergoing PVI between 1 January 2016 and 1 April 2021. Baseline characteristics, pre-, peri-, and post-procedure healthcare utilization and clinical outcomes were compared before (cohort A; n = 1379) and after (Cohort B; n = 1608) implementation of the SDD protocol using bivariate and multivariate analyses. show that cohort B vs. cohort A had lower all-cause 90-day mortality (0% vs. 0.3%, P = 0.031), no differences in re-ablation < 1 year (P = 0.286), as well as in complications: bleedings (P = 0.177), tamponade < 30 days (P = 0.157), phrenic nerve injury (P = 0.984), thromboembolic complication < 72 h (P = 0.212), or vascular complications (P = 0.290). In terms of healthcare utilization and costs, cohort B had significantly less peri-procedure hospital admission costs (€721.52 vs. €1011.78, P < 0.001) and less total peri- and post-procedure costs (€840.37 vs. €1152.94, P < 0.001). Adjusted for all baseline characteristics, the post-implementation cohort showed on average €315 lower total costs per patient. Conclusion: The implementation of the SDD protocol was associated with comparable complication rates while significantly reducing both peri- and post-procedure healthcare utilization and costs, thereby enhancing patient value. This indicates a potential margin for further cost reductions and increased efficiency.

  • Real-world anticoagulant use and clinical outcomes in postoperative atrial fibrillation after coronary artery bypass grafting: a nationwide practice-based cohort from The Netherlands Heart Registration

    by Mileen R D van de Kar, Thomas J van Brakel, Saskia Houterman, Linda M de Heer, Edgar J Daeter, Marcel van ‘T Veer, Dennis van Veghel, Harry J G M Crijns, Lukas R C Dekker, Luuk C Otterspoor

    Aims: Postoperative atrial fibrillation (POAF) occurs in 15–40% of patients following coronary artery bypass grafting (CABG). Existing risk scores are unsuited to its transient nature, and evidence for long-term oral anticoagulation (OAC) remains limited. Although guidelines suggest balancing thromboembolic and bleeding risk, unclear recommendations and limited real-world data drive practice variation. This study evaluated OAC use and outcomes in a national POAF cohort after CABG. Methods and results: This retrospective study included adults undergoing isolated CABG (2013–2022) from the Netherlands Heart Registration, linked to mortality and pharmacological data from Statistics Netherlands. Patients with prior atrial fibrillation or preoperative OAC were excluded. Outcomes included short-term complications and long-term cause-specific mortality, comparing OAC with antiplatelets. Among 44 601 CABG patients, 11 054 (24.8%) developed POAF. Of these, 10 750 were successfully linked. Mean age was 68.9 years; 81.7% were male. OAC therapy was initiated in 43.6% of patients, rising from 38.7% (2013) to 53.7% (2022). Within 30 days, mortality was 1.6%, cerebrovascular events 1.3%, and bleeding reintervention 5.4%. Most discontinued OAC after 1 year, while 10.3% continued for 10 years. Crude thromboembolic mortality was lower among OAC users (0.04 vs. 0.42 per 100 patient-years), while bleeding-related mortality remained low (0.00 vs. 0.08). However, survival analyses from 30 days postoperatively showed no significant differences between groups. Conclusion: Among POAF patients after CABG, crude mortality was lower in OAC users, but no survival benefit was observed from 30 days onward. Low long-term OAC continuation without excess thromboembolic mortality suggests the potential value of time-limited anticoagulation strategies.


  • Open Access

    Association between quality of life and redo procedures after pulmonary vein isolation in atrial fibrillation patients: Data from the Netherlands Heart Registration

    by Mileen R.D. van de Kar, Gijs J. van Steenbergen, Jasper R. Vermeer, Jeroen F. van der Heijden, Jippe F. Balt, Justin G.L.M. Luermans, Yuri Blaauw, Niki M. Medendorp, Daniela N. Veldman-Schulz, Lukas R.C. Dekker, et al.


  • Open Access

    A cost-consequence analysis comparing three cardiac ablation strategies for the treatment of paroxysmal atrial fibrillation

    by Mileen van de Kar, Lukas Dekker, Ines Timmermanns, Domenico Della Rocca, Gian-Battista Chierchia, Lise Da Riis-Vestergaard, Steffen Uffenorde, John Morgan, Julian Chun


  • Anticoagulation for post-operative atrial fibrillation after isolated coronary artery bypass grafting: a meta-analysis

    by Mileen R D van de Kar, Thomas J van Brakel, Marcel Van’t Veer, Gijs J van Steenbergen, Edgar J Daeter, Harry J G M Crijns, Dennis van Veghel, Lukas R C Dekker, Luuk C Otterspoor

    Background and Aims: This study aimed to evaluate clinical outcomes in patients developing post-operative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) and characterize variations in oral anticoagulation (OAC) use, benefits, and complications. Methods: A systematic search identified studies on new-onset POAF after CABG and OAC initiation. Outcomes included risks of thromboembolic events, bleeding, and mortality. Furthermore, a meta-analysis was conducted on these outcomes, stratified by the use or non-use of OAC. Results: The identified studies were all non-randomized. Among 1 698 307 CABG patients, POAF incidence ranged from 7.9% to 37.6%. Of all POAF patients, 15.5% received OAC. Within 30 days, thromboembolic events occurred at rates of 1.0% (POAF: 0.3%; non-POAF: 0.8%) with 2.0% mortality (POAF: 1.0%; non-POAF: 0.5%). Bleeding rates were 1.1% for POAF patients and 2.7% for non-POAF patients. Over a median of 4.6 years, POAF patients had 1.73 thromboembolic events, 3.39 mortality, and 2.00 bleeding events per 100 person-years; non-POAF patients had 1.14, 2.19, and 1.60, respectively. No significant differences in thromboembolic risks [effect size −0.11 (−0.36 to 0.13)] and mortality [effect size −0.07 (−0.21 to 0.07)] were observed between OAC users and non-users. However, OAC use was associated with higher bleeding risk [effect size 0.32 (0.06–0.58)]. Conclusions: In multiple timeframes following CABG, the incidence of complications in patients who develop POAF is low. The use of OAC in patients with POAF after CABG is associated with increased bleeding risk.


  • Open Access

    Pulsed field versus cryoballoon ablation for atrial fibrillation: a real-world observational study on procedural outcomes and efficacy

    by Mileen R. D. van de Kar, Stacey R. Slingerland, Gijs J. van Steenbergen, Tim Brouwer, Daniela N. Schulz, Dennis van Veghel, Lukas Dekker

    Introduction: Atrial fibrillation often necessitates catheter ablation when antiarrhythmic drug therapy fails. Single-shot technologies using thermal energy, such as cryoballoon ablation, are commonly used, but pulsed field ablation (PFA), an innovative non-thermal ablation technique, is a potential alternative. This retrospective observational study aimed to compare the safety and efficacy of cryoballoon ablation and PFA in patients undergoing their first pulmonary vein isolation (PVI) procedure for atrial fibrillation treatment. Methods: We utilised real-world data from patients who underwent PVI using cryoballoon ablation or PFA. The primary outcome encompassed procedural complications, including phrenic nerve palsy, cardiac tamponade, thromboembolic complications, bleeding complications and mortality. Secondary outcomes were procedural characteristics including procedure duration, length of hospital admission, and re-do ablation rates within 6 months. Results: A total of 1714 procedures were analysed: 1241 in the cryoballoon group and 473 in the PFA group. Gender distribution (p = 0.03) and estimated glomerular filtration rate (p = 0.01) differed significantly. With regard to the primary outcome, the cryoballoon group demonstrated a higher incidence of phrenic nerve palsy compared with the PFA group (15 vs 0; p = 0.02). The procedure duration was shorter in the PFA group, even after adjusting for baseline characteristics (95.0 vs 74.0 min; p < 0.001). After adjustment for baseline characteristics, admission duration differed between the groups as well (p = 0.04). Conclusion: The study results supported the safety and efficacy of PFA over cryoballoon ablation for PVI, highlighting advantages such as shorter procedure duration and absence of phrenic nerve palsy.


  • Open Access

    Hypothermia for Cardioprotection in Patients with St-Elevation Myocardial Infarction: Do Not Give It the Cold Shoulder Yet!

    by Mohamed El Farissi, Thomas P. Mast, Mileen R. D. van de Kar, Daimy M. M. Dillen, Jesse P. A. Demandt, Fabienne E. Vervaat, Rob Eerdekens, Simon A. G. Dello, Danielle C. Keulards, Jo M. Zelis, et al.

    The timely revascularization of an occluded coronary artery is the cornerstone of treatment in patients with ST-elevation myocardial infarction (STEMI). As essential as this treatment is, it can also cause additional damage to cardiomyocytes that were still viable before reperfusion, increasing infarct size. This has been termed “myocardial reperfusion injury”. To date, there is still no effective treatment for myocardial reperfusion injury in patients with STEMI. While numerous attempts have been made to overcome this hurdle with various experimental therapies, the common denominator of these therapies is that, although they often work in the preclinical setting, they fail to demonstrate the same results in human trials. Hypothermia is an example of such a therapy. Although promising results were derived from experimental studies, multiple randomized controlled trials failed to do the same. This review includes a discussion of hypothermia as a potential treatment for myocardial reperfusion injury, including lessons learned from previous (negative) trials, advanced techniques and materials in current hypothermic treatment, and the possible future of hypothermia for cardioprotection in patients with STEMI.